Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(165 products)
- Bcr-Abl(118 products)
- EGFR(586 products)
- FAK(72 products)
- FLT(89 products)
- Fibroblast Growth Factor Receptor (FGFR)(180 products)
- JAK(245 products)
- PDGFR(129 products)
- RAAS(88 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(54 products)
- VDA(2 products)
- VEGFR(245 products)
Show 6 more subcategories
Found 2275 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
YLIU-4-105-1
CAS:YLIU-4-105-1 is a type II JAK2 inhibitor. Demonstrating in vivo pharmacological activity, YLIU-4-105-1 reduces splenic weight, decreases blood reticulocyte counts in a dose-dependent manner, and inhibits pSTAT5.Formula:C32H34F3N7O2Color and Shape:SolidMolecular weight:605.65CLM3
CAS:CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.Formula:C21H21N5Color and Shape:SolidMolecular weight:343.43VEGFR-2/DHFR-IN-1
Compound 8b inhibits VEGFR-2/DHFR, combats various bacteria, and fights cancer cells.Formula:C20H18ClNO4Color and Shape:SolidMolecular weight:371.81VEGFR2-IN-1
CAS:VEGFR2-IN-1 is a VEGFR2 inhibitor with antitumor activity used in the study of breast cancer.Formula:C22H18N6SPurity:98.15%Color and Shape:SolidMolecular weight:398.48CEE321
CAS:CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.Formula:C18H16ClN5OColor and Shape:SolidMolecular weight:353.806BTK-IN-38
CAS:BTK-IN-38 (Example 125) is an efficacious inhibitor of BTK. It effectively suppresses the proliferation of DOHH2 and BT474 cells, with IC50 values of 114 nM and 340 nM, respectively.Formula:C27H26F2N4O2Color and Shape:SolidMolecular weight:476.52Hypothemycin
CAS:Hypothemycin, a fungal polyketide, inhibits multiple kinases (VEGFR, MEK, FLT-3, PDGFR, ERK) with Kis ranging from 10 nM to 2.4 μM.Formula:C19H22O8Purity:98%Color and Shape:SolidMolecular weight:378.37FAK-IN-4
FAK-IN-4 (Compound 7d) has anticancer activities that can induce cell apoptosis. FAK-IN-4 is potential inhibitor of FAK [1].Formula:C20H22N4OColor and Shape:SolidMolecular weight:334.41SYHA1815
CAS:SYHA1815, an orally active RET inhibitor (IC50=0.9 nmol/L), demonstrates antitumor activity. It exhibits greater selectivity for RET over KDR (IC50=15.9 nmol/L). SYHA1815 operates by downregulating c-Myc, arresting the G1 cell cycle, and inhibiting RET-driven cell proliferation.Formula:C27H26ClF4N5OColor and Shape:SolidMolecular weight:547.98(S)-3-Hydroxy Midostaurin
CAS:(S)-3-Hydroxy Midostaurin is a potent inhibitor of kinases(IC50 of <400 nM for 13 kinases (VEGFR-2, TRK-A, FLT3, et)).Formula:C35H30N4O5Purity:98%Color and Shape:SolidMolecular weight:586.64I194496
CAS:I194496 is an effective inhibitor of cystathionine γ-lyase (CSE) with an IC50 value of 0.79 mM. It inhibits the growth of human TNBC cells by dual targeting the PI3K/Akt and Ras/Raf/ERK pathways. Additionally, I194496 suppresses the metastasis of human TNBC cells by downregulating the Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways.Formula:C28H23F2N5O5SColor and Shape:SolidMolecular weight:579.58HER2-IN-7
CAS:HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Formula:C28H26F3N7O3Color and Shape:SolidMolecular weight:565.55JAK3-IN-11
CAS:JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.Formula:C23H23N5O2Color and Shape:SolidMolecular weight:401.46HDAC-IN-35
HDAC-IN-35 (Compound 14) is an effective and selective inhibitor of VEGFR-2 and HDAC, with IC50 values of 13.2 and 0.166 μM for VEGFR-2 and HDAC6, respectively.Formula:C17H13ClF3N3O3Color and Shape:SolidMolecular weight:399.75EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Color and Shape:SolidOXA-11
CAS:OXA-11 (FAK-IN-16) is a FAK inhibitor with anti-tumor activity, useful for cancer research.Formula:C37H49F3N7O5PPurity:98.70% - 99.20%Color and Shape:SolidMolecular weight:759.8Multi-kinase inhibitor 3
CAS:Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.Formula:C26H26N6O2Color and Shape:SolidMolecular weight:454.52AKN-028 acetate
AKN-028 acetate: an oral TK inhibitor for AML research, targets FLT3 with IC50 of 6 nM, inhibits autophosphorylation, and induces apoptosis.Formula:C19H18N6O2Color and Shape:SolidMolecular weight:362.39VEGFR-2-IN-18
VEGFR-2-IN-18 is a potent VEGFR-2 inhibitor with a 60 nM IC50, promoting cell apoptosis and anticancer effects.Formula:C20H13ClN4O2Color and Shape:SolidMolecular weight:376.8EGFR-IN-47
EGFR-IN-47: strong oral EGFRL858R/T790M/C797S blocker, induces cell death; promising for NSCLC research. IC50: 0.01 μM.Formula:C29H35N7Color and Shape:SolidMolecular weight:481.64SJ-C1044
CAS:SJ-C1044 is an orally effective pan-RAF inhibitor demonstrating immunomodulatory and antitumor activities. It targets wild-type BRAF, wild-type CRAF, and BRAF(V600E) with IC50 values of 331, 257, and 187 nM, respectively. SJ-C1044 suppresses tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. Additionally, it shows inhibition of VEGFR2, TIE2, and CSF1R, with IC50 values of 100, 23, and 235 nM respectively. The compound enhances the tumor immune microenvironment through inhibition of angiogenesis and modulation of macrophage function. SJ-C1044 is applicable for research in colorectal cancer.Formula:C25H14F7N7OColor and Shape:SolidMolecular weight:561.41VEGFR-2-IN-26
CAS:VEGFR-2-IN-26 inhibits VEGFR-2 (IC50: 15.5 nM), combating various cancers' cell growth.Formula:C24H19F3N6O2Color and Shape:SolidMolecular weight:480.44JAK-IN-19
JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).Formula:C26H36FN5O2Color and Shape:SolidMolecular weight:469.59Tofacitinib Prodrug-1
Tofacitinib Prodrug-1: an oral prodrug reducing Tofacitinib's side effects, treats ulcerative colitis in mice effectively with low toxicity.Formula:C36H39ClN10O7Color and Shape:SolidMolecular weight:759.21EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Color and Shape:SolidOxamic acid
CAS:Oxamic acid is an LDHA inhibitor, antitumor, induces apoptosis, downregulates EGFR expression, and inhibits cancer stem cell properties and EMT.Formula:C2H3NO3Color and Shape:SolidMolecular weight:89.05JAK-2/3-IN-3
JAK-2-/3-IN-3 (ST4j) is a potent JAK2/3 inhibitor for leukemia research, with IC50s: JAK2, 13 nM; JAK3, 14.86 nM; induces apoptosis.Formula:C13H10Cl2N4O2Color and Shape:SolidMolecular weight:325.15BMS-986143
CAS:BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Formula:C31H24Cl2N4O4Color and Shape:SolidMolecular weight:587.45JAK3/BTK-IN-4
CAS:JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Formula:C21H25ClN8OColor and Shape:SolidMolecular weight:440.93MTX-216
CAS:MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.Formula:C22H14Cl2FN5O2SColor and Shape:SolidMolecular weight:502.348BPI-15086
CAS:BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.Formula:C29H33ClN8O4Color and Shape:SolidMolecular weight:593.08FLT3-IN-13
FLT3-IN-13 inhibits topoisomerase II/FLT3 in leukemia with IC50 of 2.26 μM, causes G2/M arrest, and promotes apoptosis.Formula:C20H14N4O2Color and Shape:SolidMolecular weight:342.35Cernuumolide J
CAS:Cernuumolide J (TMJ-105) functions as a JAK2/STAT3 inhibitor and exhibits potent activity against HEL leukemia cells by inhibiting their growth in both time-dependent and concentration-dependent manners, with an IC 50 value of 1.79 μM. This compound effectively induces G2/M phase arrest and apoptosis by downregulating the phosphorylation of JAK2, STAT3, and Erk, while simultaneously upregulating the phosphorylation of JNK and p38 MAPK. Cernuumolide J holds potential for research applications in anti-cancer therapy.Formula:C24H34O8Color and Shape:SolidMolecular weight:450.52FGFR-IN-16
CAS:FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, exhibiting IC50 values of 8 nM, 4 nM, and 3.8 nM respectively. It plays a crucial role in cancer research.Formula:C30H27Cl2N7O4Color and Shape:SolidMolecular weight:620.49EGFR-IN-146
CAS:EGFR-IN-146 is an EGFR inhibitor that suppresses the EGFR signaling pathway and improves insulin sensitivity by activating the AMPK pathway. It effectively reduces blood glucose levels and body weight, showing great potential in the study of diabetes and obesity.Formula:C20H16N4Color and Shape:SolidMolecular weight:312.368Lomonitinib
CAS:Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.
Formula:C27H24N4O2Color and Shape:SolidMolecular weight:436.505FGFR-IN-15
FGFR-IN-15 (compound 18i) acts as a pan-FGFR inhibitor, exhibiting potent inhibitory activity against FGFR1-4.Formula:C22H23N5O5SColor and Shape:SolidMolecular weight:469.51HER2-IN-12
HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.Formula:C17H18BrN5O2SColor and Shape:SolidMolecular weight:436.33Tandutinib sulfate
CAS:Tandutinib (MLN518) sulfate is an effective and selective inhibitor of FLT3, with an IC50 value of 0.22 μM. It also inhibits c-Kit and PDGFR, displaying IC50 values of 0.17 μM and 0.20 μM respectively. This compound can be utilized in the treatment of acute myeloid leukemia and has the capability to cross the blood-brain barrier.Formula:C31H44N6O8SColor and Shape:SolidMolecular weight:660.78VEGFR-IN-3
CAS:VEGFR-IN-3 inhibits cancer cell growth (OVCAR-4, MDA-MB-468) with IC50s: 0.29, 0.35μM. Used in cancer research.Formula:C27H28N2O6Color and Shape:SolidMolecular weight:476.52JNJ-47117096
CAS:JNJ-47117096 is a potent and selective MELK inhibitor with an IC50 of 23 nM, and it also exhibits strong activity against Flt3 with an IC50 of 18 nM.Formula:C21H22N4O2Color and Shape:SolidMolecular weight:362.425EGFR/VEGFR2-IN-3
CAS:EGFR/VEGFR2-IN-3 (compound 9) is an effective inhibitor of EGFR and VEGFR-2, demonstrating IC50 values of 0.129 µM for EGFR, 0.142 µM for VEGFR-2, and 3.428 µM for COX-2. This compound exhibits cytotoxic properties and induces cell apoptosis (apoptosis) as well as cell cycle arrest at the G2/M phase.Formula:C24H20ClN5O2S2Color and Shape:SolidMolecular weight:510.03Tyk2-IN-10
CAS:Tyk2-IN-10 acts as an inhibitor of the Tyrosine Kinase 2 (Tyk2)-mediated signaling pathway, which plays a role in inflammation regulation.Formula:C25H27N5O3Color and Shape:SolidMolecular weight:445.51MM-589
CAS:MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Formula:C28H44N8O5Purity:98%Color and Shape:SolidMolecular weight:572.70VEGFR-2-IN-52
CAS:VEGFR-2-IN-52 (compound 14d) serves as a powerful inhibitor of VEGFR-2, exhibiting an IC 50 of 191.1 nM. It effectively reduces the protein expression levels of p-VEGFR-2, MMP9, p-ERK1/2, and p-MEK1. In addition, VEGFR-2-IN-52 demonstrates cytotoxic properties by inducing apoptosis and arresting the cell cycle at the G0/G1 phase, and it enhances the levels of ROS.Formula:C20H25ClN4O2SColor and Shape:SolidMolecular weight:420.96VEGFR-2-IN-10
VEGFR-2-IN-10 has enhanced antiangiogenic potency against VEGFR2 phosphorylation induced by VEGF with an IC50 value of 0.7 μM and no cytotoxic effects.Formula:C20H21N3O2Color and Shape:SolidMolecular weight:335.4JAK2/FLT3-IN-1 TFA
JAK2/FLT3-IN-1 (TFA), an oral JAK2/FLT3 inhibitor, shows anticancer properties; IC50: JAK2 (0.7 nM), FLT3 (4 nM), JAK1 (26 nM), JAK3 (39 nM).Formula:C27H35F4N7O3Color and Shape:SolidMolecular weight:581.61EGFR-IN-130
EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.Formula:C27H25N3O6SColor and Shape:SolidMolecular weight:519.57BTK-IN-32
CAS:BTK-IN-32 (compound C2) acts as a potent BTK inhibitor. Unlike isolated kinase domains, this compound activates full-length BTK as well as its smaller multidomain fragments [1].Formula:C35H35ClN4O3SColor and Shape:SolidMolecular weight:627.2EGFR-IN-139
CAS:EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).Formula:C27H25ClN2O4Color and Shape:SolidMolecular weight:476.951EGFR-IN-133
CAS:EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.Formula:C27H29F2N7O3Color and Shape:SolidMolecular weight:537.56EGFR/BRAF-IN-1
EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.Formula:C26H28ClN3O4Color and Shape:SolidMolecular weight:481.97Andamertinib
CAS:Andamertinib is an EGFR inhibitor with antitumor activity.Formula:C31H36N8O3Color and Shape:SolidMolecular weight:568.669Lucitanib dihydrochloride
CAS:Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient VEGFR1-3, FGFR1-3, and PDGFRalpha/β inhibitor, used in metastatic breast cancer research.Formula:C26H27Cl2N3O4Color and Shape:SolidMolecular weight:516.42Vatalanib hydrochloride
CAS:Vatalanib hydrochloride (PTK787 hydrochloride) is an orally available and highly potent tyrosine kinase (VEGF) inhibitor that reduces the number and size of Aβ plaques in the cortex of 5xFAD mice, which may be useful in the study of Alzheimer's disease and cancer.Formula:C20H16Cl2N4Purity:99.7%Color and Shape:SolidMolecular weight:383.27NDI-034858
CAS:NDI-034858 (TAK-279) is a tyrosine kinase 2 (TYK2) inhibitor (Kd<200 pM) that targets the JH2 structural domain of Tyk2 for the treatment of autoimmune diseasesFormula:C23H24N8O3Purity:>99.99%Color and Shape:SolidMolecular weight:460.49JDTic
CAS:JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Formula:C28H39N3O3Color and Shape:SolidMolecular weight:465.63JAK2-IN-7
CAS:JAK2-IN-7 selectively inhibits JAK2 (IC50: 3 nM), shows 14-fold selectivity over JAK1/3, FLT3, induces G0/G1 arrest, apoptosis, and has antitumor effects.Formula:C26H33N7OPurity:99.54%Color and Shape:SolidMolecular weight:459.59Ref: TM-T35900
1mg145.00€5mg354.00€10mg630.00€25mg1,301.00€50mg1,738.00€100mg2,357.00€1mL*10mM (DMSO)358.00€XMD-17-51 Trifluoroacetate
CAS:XMD-17-51 Trifluoroacetate is a pyrimido-diazepinone compound that regulates protein kinases.Formula:C23H25F3N8O3Purity:99.65%Color and Shape:SolidMolecular weight:518.49Ibrutinib Racemate
CAS:Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.Formula:C25H24N6O2Purity:98%Color and Shape:SolidMolecular weight:440.5Imbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Color and Shape:Odour LiquidNimotuzumab (powder)
CAS:Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.
Color and Shape:Liquid(3R,4S)-Tofacitinib
CAS:(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Formula:C16H20N6OPurity:98%Color and Shape:SolidMolecular weight:312.37XMU-MP-3
CAS:XMU-MP-3 is a robust, non-covalent inhibitor of BTK, exhibiting exceptional potency with IC50 values of 10.7 nM and 17.0 nM for BTK WT and BTK C481S mutation, respectively, in the presence of 10 μM ATP. Moreover, XMU-MP-3 elicits apoptosis.Formula:C27H27F3N8OColor and Shape:SolidMolecular weight:536.563Dihydrodiol-Ibrutinib
CAS:PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Formula:C25H26N6O4Color and Shape:SolidMolecular weight:474.521HMBD-001
HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.
Color and Shape:Odour LiquidENMD-2076 tartrate
CAS:ENMD-2076 is an orally active kinase inhibitor. It also has antiangiogenic and antiproliferative mechanisms of action.Formula:C25H31N7O6Color and Shape:SolidMolecular weight:525.56PM-8002
PM-8002 is a bispecific antibody that targets PD-L1 and VEGF-A. It is applicable for research on solid tumors.
Color and Shape:Odour LiquidTLC9995-0188
CAS:Tyrosine-protein kinase ABL, IC50: 1500 nMFormula:C16H15N5Color and Shape:Yellow SolidMolecular weight:277.331Desidustat
CAS:Desidustat is an inhibitor of HIF hydroxylase.
Formula:C16H16N2O6Purity:98%Color and Shape:SolidMolecular weight:332.31Olmutinib
CAS:Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormula:C26H26N6O2SPurity:99.14%Color and Shape:SolidMolecular weight:486.59PF-03814735
CAS:PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.Formula:C23H25F3N6O2Purity:98%Color and Shape:SolidMolecular weight:474.48Duligotuzumab
CAS:Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.
Purity:95%Color and Shape:LiquidRef: TM-T80604
Discontinued product3,3',4,4'-Tetrabromobiphenyl
CAS:Controlled ProductApplications 3,3',4,4'-Tetrabromobiphenyl is multi-persistent organic pollutants analyzed in breast milk of first time mothers. An environmental pollutant that affects copper and molybdenum metabolism in rats. Also, it is derived from 1-Bromo-2- nitrobenze (B686175), which is an organic building block used for the synthesis of various pharmaceutical compounds. It is an intermediate for the synthesis of novel Diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity.
References Tlustos, C., et al.: Organohalogen Compd., 75, 1185-1188 (2013); Salman, K. N., et al.: Environ. Sci. Pollut. R., 21, 6400-6409 (2014); Dao, P., et al.: Bioorg. Med. Chem. Lett., 23, 4552 (2013);Formula:C12H6Br4Color and Shape:Off-White To Light BrownMolecular weight:469.79VEGFR-IN-1
CAS:VEGFR inhibitorFormula:C19H16ClN3OPurity:98%Color and Shape:SolidMolecular weight:337.8
